Abstract Background The randomized, double-blind, phase 3 LITESPARK-022 study (NCT05239728) showed significant disease-free survival benefit with the addition of belzutifan to adjuvant pembrolizumab in participants with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence following surgery. We presen...
T. Powles, T. Choueiri, J. Karam et al.· The Oncologist· 0 citations
Kidney cancer is one of the 10 most common cancers affecting both men and women in the United States, accounting for 4% to 5% of all cancers. Most recent estimates have shown that about 81,610 new cases of kidney cancer will be diagnosed in 2024, with renal cell carcinoma (RCC). The treatment landscape of metastatic or...
Firas Hatoum, Brandon J. Dyer, Jazlyn Heiligh et al.· Future Oncology· 0 citations
This review evaluates biomarkers at three clinical decision points: characterization of an indeterminate renal mass; recurrence-risk assessment and adjuvant treatment selection after nephrectomy; and first-line regimen selection in metastatic ccRCC.
Hadi Al Etri, Lea Al Zoghby, Mohamad Sadek Zoghbi et al.· Genes· 0 citations
The TRAVERSE trial demonstrates proof of concept for the role of allogeneic CAR T-cell therapy in solid tumors and had manageable safety and encouraging antitumor activity in CD70-positive ccRCC.
S. Srour, J. Chahoud, A. Drakaki et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
